AQST - Company ID 0001398733
The table below shows Aquestive Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$52.43M | -$35.76M | -$6.38M | -$9.82M | -$32.98M | -$45.46M |
| Capital expenditure | $562.00K | $159.00K | $995.00K | $1.02M | $913.00K | $517.00K |
| Investing cash flow | -$562.00K | -$159.00K | -$995.00K | -$2.52M | -$913.00K | -$517.00K |
| Dividends paid | - | - | - |
Aquestive Therapeutics, Inc. reported operating cash flow of -$52.43M for fiscal year 2025. That is down 46.6% from -$35.76M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from $5.82M (FY 2017) to -$52.43M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $102.62M | $83.59M | $3.97M | $11.59M | $30.11M | $28.46M |